Navigation Links
Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
Date:7/25/2008

SCHAUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched amiodarone HCl injection, USP, a class III antiarrhythmic indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia -- a potentially life-threatening irregular heart beat. Sagent's amiodarone HCl injection will be available immediately in 150 mg/3 mL single dose prefilled syringes. According to IMS data, 2007 sales of injectable amiodarone in the United States were approximately $8 million. Amiodarone prefilled syringes are manufactured for Sagent by Gland Pharma.

"With our launch of the only multi-source, prefilled amiodarone syringe in the health care market, Sagent is making another essential product readily available to the emergency medicine community," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "In the emergency room, where seconds count, our product is ready-to-use -- and with enhanced labeling, easy to find on a crash cart. We are proud that our innovations to this important product, including a tamper-evident tip cap, yield safety enhancements that will potentially assist in saving patient's lives."

Amiodarone is the eighth product introduced from Sagent's pipeline of more than 200 products since the launch of the company's first product in December 2007.

About Amiodarone

Amiodarone HCl Injection, USP, is a class III antiarrhythmic indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Intravenous amiodarone can also be used to treat patients with ventricular fibrillation or ventricular tachycardia for whom oral amiodarone is indicated but who are not able to take oral medication. During or after treatment with intravenous amiodarone, patients may be transferred to oral amiodarone therapy. Intravenous amiodarone should be used for acute treatment until the patient's ventricular arrhythmias are stabilized.

The most common adverse effects may include dizziness or drowsiness; nausea, vomiting, stomach pain; insomnia; weakness, lack of coordination; or warmth, tingling or redness under the skin. Less common adverse effects include a new or worsening irregular heartbeat; wheezing, cough, chest pain, trouble breathing, coughing up blood; blurred vision, headache or pain behind the eyes; rapid weight gain; weight loss, thinning hair, increased sweating, irregular menstrual periods, swelling in the neck; numbness, burning, pain or tingling in the hands or feet; loss of appetite, dark urine, clay-colored stools, jaundice.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.

About Gland Pharma Ltd.

Established in 1978 as an exclusive facility for Small Volume Parenterals (SVPs), Gland Pharma has developed into a progressive and quality conscious organization serving the pharmaceutical needs of more than 25 countries across the globe. Gland Pharma has world-class and world-scale facilities for injectables set up in collaboration with the Vetter Group, Germany. Gland Pharma's research and development operation develops niche products from active pharmaceutical ingredient to finished dosages. Adenosine is one of many approved abbreviated new drug applications from the Gland Pharma's growing portfolio.

For more information about Gland Pharma, please visit http://www.glandpharma.com


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
2. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
3. New Natural Product from Zurich Pharmaceuticals Downs Appetite
4. AUDIO from Medialink and Duramed Pharmaceuticals: Not Your Mothers Menopause
5. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
6. Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
7. AUDIO from Medialink and Duramed Pharmaceuticals: Relief for Women Experiencing Surgical Menopause
8. Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
9. Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer
10. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
11. Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: